Genome and Hormones: Gender Differences in Physiology
http://www.100md.com
《应用生理学杂志》
D. A. Lewis, M. P. Bracamonte, K. S. Rud, and V. M. Miller
Departments of Surgery, and Physiology and Biophysics, Mayo Clinic and Foundation, Rochester, Minnesota 55905
ABSTRACT
Estrogen replacement increases risk of venous thrombosis. In this study, we determined responses in vitro to platelets and platelet products in veins from adult male and intact and ovariectomized female pigs. When contracted with prostaglandin F2, platelets (25,000 platelets/μl) caused relaxation in veins with endothelium. Higher numbers of platelets caused contraction in veins with and without endothelium. In veins without endothelium, contractions were greater in veins from male than in veins from female pigs, and contractions in intact female pig veins were greater than in ovariectomized females pig veins. Platelet products 5-hydroxytryptamine and thromboxane (analog U-46619) caused comparable contractions in all veins; contractions to prostacyclin were less in veins from intact female pigs. ADP caused comparable endothelium-dependent relaxations in all groups. These relaxations were increased by indomethacin in veins from intact males and females; with inhibition of nitric oxide, relaxations were comparable in all groups. These results suggest that venous responses to platelets vary with sex and presence of ovaries in female pigs. These variations reflect differences in type and quantity of substances released from platelets as well as the sensitivity of the smooth muscle to some vasoactive substances. In addition, products of cyclooxygenase may reduce endothelium-dependent relaxations in veins.
keywords:estrogen; venous thrombosis
INTRODUCTION
OBSERVATIONAL AND EPIDEMIOLOGICAL studies indicate that the incidence of arterial cardiovascular disease is less in premenopausal women compared with age-matched men. The incidence of cardiovascular disease increases with menopause, and estrogen-replacement therapy provides primary protection against the development of cardiovascular disease (8, 30, 49, 51). However, although estrogen replacement provides primary protection against development of arterial vascular disease in women, it increases risk for venous thrombosis (16, 21, 24, 29). Estrogen therapy in men also increases the risk of venous thrombosis (13, 50).
Responses of arteries to various vasoactive substances vary by the sex of the animal from which the tissue is derived. Some of these differences are partly due to actions of estrogen on the arterial wall through several mechanisms, including regulation of ion fluxes and receptors on the smooth muscle and production of endothelium-derived factors (6, 7, 12, 15, 18-20, 22, 41-43, 46, 47, 56). No studies have examined sex differences in responses of veins to substances associated with platelet aggregation or thrombosis. This information is important because synthetic estrogen-like compounds (selective estrogen receptor modulators or SERMS) are being developed for tissue-specific therapies for use in both men and women. Two such compounds now in clinical use, tamoxifen and raloxifene, also increase risk for venous thrombosis in women (1, 17). If SERMS are to be used for cardioprotection, it is important to identify potential gender differences not only in arteries but also in veins so that the risk of venous thrombosis can be reduced in both men and women.
Previous work from our laboratory (37) identified differences in the content of platelets from male and female pigs: platelets from adult male pigs contained more thromboxane, whereas platelets from ovariectomized female pigs contained more prostacyclin and 5-hydroxytryptamine (5-HT). However, acute vasomotor responses of the coronary arteries to platelets were found not to vary by sex of the animals (37). The present study was designed to compare responses to platelets and platelet-derived products in veins from gonadally intact male and female animals and to identify whether depletion of ovarian hormone alters the responses in female animals.
METHODS
Femoral veins from 6-mo-old male (139.5 ± 10.2 kg), female (94.4 ± 2.2 kg), and ovariectomized female (87.4 ± 1.4 kg) Yorkshire pigs were used in these experiments. Ovariectomy was performed when female animals were 5 mo old, and veins were removed 4 wk postoperatively. All animals were fed Lean Grow 93 (Land O'Lakes Farmland Feed, Fort Dodge, IA). Gonadally intact females showed changes in their external genitalia associated with changes in their estrus cycle. Estradiol levels typically range from 5 to 35 pg/ml in intact female pigs, are below the level of assay sensitivity in ovariectomized female pigs, and range from 25 to 55 pg/ml in male pigs (4, 5, 54). Testosterone averages 324 ± 99 pg/ml in male pigs (4, 5, 54). Animals were anesthetized with a combination of ketamine hydrochloride (30 mg/kg), xylazine (6 mg/kg), and butorphanol (0.3 mg/kg) intramuscularly. Blood (500 ml) was obtained from the carotid artery for preparation of platelets (see Platelet Preparation below). Femoral veins were excised bilaterally and placed in cold modified Krebs-Ringer bicarbonate solution (control solution), which contained (in mmol/l) 118.3 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25.0 NaHCO3, 0.026 edentate calcium disodium, and 11.1 glucose. Coronary arteries from these animals were studied in separate experiments (5, 37).
Organ Chamber Experiments
After we removed the adventitia, femoral veins were cut into rings; rings that contained valves were excluded from the study. In some rings, the endothelium was removed by gently rubbing the luminal surface with watchmaker's forceps. Because veins vary in length, branching, and the presence of valves, it was not possible to obtain the same number of rings from all animals. However, pairs of rings with and without endothelium or in the absence and presence of either indomethacin (105 mol/l) or NG-monomethyl-L-arginine (L-NMMA, 104 mol/l) plus indomethacin were studied in parallel from a single animal.
Rings were suspended between a fixed point and a force transducer (Statham UC-2) in organ chambers (25 ml) containing control solution at 37°C and were bubbled with 95% O2-5% CO2.
Passive tension on the rings was progressively increased. Active tension to norepinephrine (3 × 107 mol/l) was measured at each passive tension until each ring reached its optimal point on the length-tension curve. Maximal tension to KCl (60 mmol/l) was obtained in all rings. From a given animal, rings with and without endothelium or in the absence and presence of inhibitors were then studied in one of three experimental protocols (protocol A, B, or C).
Experimental protocol A. Rings were contracted with prostaglandin F2 (2 × 106 mol/l), and, once the contraction plateaued, concentration-response curves to ADP (1 × 108 to 1 × 104 mol/l) were obtained. After a washout and equilibration period, responses to autologous platelets (25,000, 50,000, and 75,000 platelets/μl) were obtained during a second contraction to prostaglandin F2.
Experimental protocol B. Concentration-response curves to 5-HT (1 × 1010 to 1 × 106 mol/l) were obtained from baseline tension. After a washout and equilibration period, rings were contracted with prostaglandin F2 (2 × 106 mol/l) and cumulative responses to thrombin (0.01, 0.1 & 1.0 U/ml) were obtained, followed by the calcium ionophore A-23187 (1 × 109 to 1 × 106 mol/l) in rings with endothelium or by nitric oxide (3 × 109 to 1 × 105 mol/l) in rings without endothelium.
Experimental protocol C. Cumulative concentration-response curves were obtained to either the thromboxane mimetic U-46619 (109 to 106 mol/l) or prostacyclin (109 to 105 mol/l) from baseline tension.
In all protocols, at the conclusion of each concentration-response curve measurement, rings were washed with control solution three times. A minimum 20-min equilibration was allowed in all experiments before the next antagonist was tested. Once an inhibitor was added to a chamber, it remained in contact with the tissue for each subsequent stimulation.
Platelet Preparation
Platelets were isolated as previously described (14, 25). Briefly, blood (500 ml) was drawn from the carotid artery into 50-ml centrifuge tubes containing an initial acid citrate dextrose solution [ACD 1, which contained (in mmol/l) 93 sodium citrate, 70 citric acid, and 140 dextrose] so that the concentration was 10 ml of blood to 1 ml of ACD 1. The blood-ACD 1 solution was centrifuged at 55 g for 40 min. The plasma was removed, and an equal volume of a second acid citrate dextrose solution [ACD 2, which contained (in mmol/l) 185.7 sodium citrate, 14 citric acid, 209.8 dextrose, and 9.9 potassium chloride] was added to each tube of plasma. The plasma-ACD 2 solution was centrifuged at 570 g for 40 min at room temperature. The supernatant was discarded, and the platelet pellet was resuspended in ACD 2 (1.25 ml ACD 2 for each 50 ml of original blood). The platelet number in this suspension was obtained by a Coulter counter. Once the platelet count in the suspension was known, volumes could be adjusted so that the final platelet concentration was standard for each experiment (25,000, 50,000, or 75,000 platelets/μl).
Calculations and Statistical Analysis
Data are expressed as means ± SE; n equals the number of pigs from which rings were taken. Data for contractions are expressed as the increase in grams of tension or as a percentage of the contraction to KCl. For relaxations, data are expressed as percent change in tension to prostaglandin F2 from a submaximal contraction. In some veins, spontaneous activity was observed. Peak tension was used as the value for which further changes in tension were measured. One-way ANOVA was performed on the calculated areas under individual concentration-response curves, maximal tensions, or, when appropriate, the concentration at 50% maximal relaxation or contraction (EC50), expressed as a negative log molar concentration. If a significant F value was found, a Bonferroni test was used to determine differences among means. Alpha level was set at 0.05.
RESULTS
The number of platelets in the prepared suspension did not differ significantly among groups: 93 ± 6 × 103 platelets/μl in male pigs (n = 14), 106 ± 10 × 103 platelets/μl in female pigs (n = 16), and 100 ± 7 × 103 platelets/μl in ovariectomized female pigs (n = 10). All rings contracted to KCl (Table 1). Contractions to KCl were similar between rings with and without endothelium within each group. However, contractions of veins with endothelium from intact female pigs were significantly less than those from veins with endothelium from male pigs (Table 1).
Responses to Platelets
Platelets at a concentration of 25,000 platelets/μl caused endothelium-dependent relaxations in veins from all groups of pigs, whereas higher concentrations of platelets caused contractions in rings with and without endothelium. In rings without endothelium, contractions were as follows: male > female > ovariectomized female pigs (Figs. 1 and 2).
Contractions to Platelet-Derived Factors
5-HT caused comparable concentration-dependent contractions of rings with and without endothelium from all groups of pigs. Absolute tension developed to 106 M 5-HT was less in veins with endothelium from females compared with male and ovariectomized pigs: 6.3 ± 0.9 g (n = 11) in males, 2.4 ± 0.4 g (n = 15) in intact females, and 6.5 ± 1.7 g (n = 9) in ovariectomized females. Tensions were not altered significantly by removal of the endothelium. When expressed as a percentage of the maximal tension to KCl, the sensitivity of veins without endothelium from ovariectomized pigs was less than that of veins from either intact male or female pigs (Fig. 3).
Both U-46619 and prostacyclin caused concentration-dependent contractions in veins with and without endothelium from all groups of pigs (Fig. 4). There was large variability in responses, especially in rings without endothelium. However, maximal contractions to prostacyclin in female pig veins without endothelium were significantly less than the contractions in ovariectomized female pig veins. Prostacyclin did not cause a significant change in tension if the veins were first contracted with prostaglandin F2 (data not shown, n = 5/group).
Relaxations to Platelet-Derived Factors
In veins with endothelium contracted with prostaglandin F2, ADP caused comparable concentration-dependent relaxations in veins from all groups of pigs (Fig. 5). However, incubation of the rings with indomethacin caused a significant increase in sensitivity and maximal relaxation in veins with endothelium from male pigs. Maximal relaxations were also increased significantly in veins from intact females. Inhibition of production of nitric oxide with L-NMMA significantly reduced maximal relaxation and decreased sensitivity in veins from male pigs but not from either intact or ovariectomized females (Fig. 6). Relaxations of rings without endothelium were not different among groups, with a maximal relaxation averaging a decrease of ~25% of the contraction to prostaglandin F2. Relaxations of rings without endothelium were not altered significantly by indomethacin alone or by the combination of indomethacin plus L-NMMA (data not shown).
Thrombin also caused concentration-dependent relaxations in veins from all groups of pigs. However, unlike responses to ADP, relaxations to thrombin were not significantly inhibited by incubation of veins with either indomethacin alone or with a combination of indomethacin plus L-NMMA (Fig. 6).
Both A-23187 and nitric oxide caused comparable relaxations of rings with and without endothelium, respectively, in veins from all groups (Fig. 7). These relaxations were unaffected by incubation of the veins with either indomethacin or a combination of indomethacin plus L-NMMA (data not shown).
DISCUSSION
Results of this study suggest that the response to platelets in veins vary depending on the sex of the animal from which they are derived and, for female animals, on the presence of ovaries. These differences were most obvious in expression of contractions to the platelets in the absence of endothelium: contractions of veins from ovariectomized female pigs were less than those from intact male and female pigs. These observations in part confirm previous studies that indicated that factors released from aggregating platelets cause endothelium-dependent relaxations in the presence of endothelium and contractions in the absence of endothelium (14, 25, 26, 32, 35). Thus an aggregation of platelets may not be retained after dilation of a blood vessel with intact endothelium. However, with either mechanical or chemical damage to the endothelium, platelet aggregation, once initiated, would cause constriction of the venous wall. The constriction-decreased cross-sectional area results in increased flow velocities through the site, which would tend to wash off excess platelets and prevent an occlusive thrombus (14). Irritability of platelets, i.e., the tendency to form an aggregate, is also increased with ovariectomy (unpublished observations from our laboratory). Ovarian hormones modulate the content of vasoactive substances in platelets (shown here and in Ref. 37) as well as other factors of the coagulation cascade involved in thrombus formation (34). Therefore, under conditions of hormone depletion and/or replacement, additional factors may affect expansion and retention of the platelet aggregate, although a normal part of hemostasis may contribute to thrombosis in pathological situations.
Contractions to platelets in veins without endothelium from ovariectomized females were significantly less than contractions of veins from intact males. This result was unexpected. Contractions to KCl were similar between veins from males and ovariectomized females, thus demonstrating similar contractile characteristics of the smooth muscle. Therefore, reduced contractions to platelet products in veins from ovariectomized compared with male pigs most likely represent differences in the various factors released from the aggregating platelets. For example, release of 5-HT and prostacyclin is greater from platelets of ovariectomized pigs compared with either intact male or female pigs (37). Platelet-derived 5-HT causes platelet-associated contractions of other blood vessels (14, 25, 26, 32, 35); indeed, 5-HT directly caused contraction of the femoral veins from these animals, albeit with a decreased sensitivity compared with veins from intact male or female animals. In addition, prostacyclin caused contraction of the veins from ovariectomized females. Therefore, prostacyclin, if released from platelets, would contribute to contraction rather than relaxation. ADP is also released from platelets (25, 26, 31) and, although not quantified in this study, causes relaxation of veins with and without endothelium (25, 26, 31). In addition, platelets contain other vasoactive and mitogenic factors, including nitric oxide, cyclic guanosine monophosphate, and platelet-derived growth factor, some of which are modulated by ovarian hormones (M. Jayachandran and V. M. Miller, unpublished observations, and Ref. 45). Nitric oxide released from platelets of ovariectomized pigs would functionally antagonize contractions to 5-HT and prostacyclin. Other studies need to quantify nitric oxide from platelets of animals of differing gonadal and hormonal status. Unpublished observations from our laboratory indicate that megakaryocytes, the precursors of platelets, contain estrogen receptors. Therefore, gonadal hormones may alter content of platelets through genomic mechanisms in these cells. Despite the lack of such quantification of all factors in platelets in the present study, it is likely that the response to aggregating platelets in veins, as in arteries, represents the cumulative effect of all platelet-derived products released during aggregation.
The diet of the pigs contained soy as one protein source. Phytoestrogens can bind to estrogen receptors and act as antioxidants. It is not known at this time how these compounds regulate estrogen receptor expression or compete with binding to receptors when endogenous estrogen is present. At least in the ovariectomized pigs that lacked endogenous ovarian hormones including estrogen, the dietary source of phytoestrogens may have modulated platelet responses such that even greater differences may have been observed between responses to platelets in veins from intact and ovariectomized pigs if the diet did not contain soy.
Responses to platelets do not only reflect differences in the content of vasoactive factors in platelets but also differences in functions of the smooth muscle and endothelium. Contractions to KCl were decreased in veins from intact female pigs compared with other groups. Ovarian hormones modulate expression of potassium channels in uterine smooth muscle (9), but similar regulation needs to be demonstrated in venous smooth muscle. Inhibition of potassium channels decreases endothelium-dependent relaxations in veins from intact female animals to a greater extent than in veins from ovariectomized female animals (M. P. Bracamonte, M. Jayachandran, K. S. Rud, and V. M. Miller, unpublished observations, and Bracamonte, Rud, and Miller, unpublished observations). Therefore, ovarian status may influence mechanisms associated with regulation of potassium and membrane polarization in veins. Sex differences in activation of potassium channels were also observed in coronary arterial smooth muscle (3, 22). It is unclear why contractions to prostacyclin are less in veins from intact female pigs compared with the other groups. Differences in activation of cAMP cannot be excluded at this time. Because relaxations to nitric oxide were similar among groups, it is unlikely that activation of soluble guanylate cyclase is altered by sex or gonadal status.
Endothelium-dependent relaxations to ADP, thrombin, or A-23187 were similar among groups. However, indomethacin had different effects on these responses in veins from male compared with female pigs, especially as related to increased relaxation to ADP in males and the tendency for decreased relaxations to thrombin in females. As in coronary arteries, endothelium-dependent relaxations in veins from male animals increased with inhibition of cyclooxygenase (5), suggesting a greater contribution of contractile products of arachidonic acid metabolism in male than in female animals. Exogenous arachidonic acid causes endothelium-dependent contractions of femoral veins from gonadally intact male dogs (39). Thromboxane synthase may be modulated by testosterone, since amounts of thromboxane measured from activated platelets were greater in male than in female animals (37). Increased amounts of thromboxane in platelets and evidence of a cyclooxygenase contractile factor from the endothelium of males suggest that products of arachidonic acid metabolism may be modulated similarly in several cell types by sex steroids. If similar conditions could be demonstrated in humans, results could account in part for the effectiveness of aspirin to limit cardiovascular disease in men (23).
Observations that inhibition of neither cyclooxygenase nor L-NMMA blocks endothelium-dependent relaxations to thrombin or A-23187 in veins are not new (36, 38, 52) and suggest release of other endothelium-derived factors; these remain to be characterized. Possible candidates for other endothelium-derived factors include products of lipoxygenase and/or C-type natriuretic factor (2, 33, 55). These factors would not only affect venous tone but also would act to release factors from the endothelium that would in turn affect platelet aggregation (40, 44, 48). Therefore, changes in risk for venous thrombosis with initiation of estrogen-replacement therapies would represent the combined effects of the hormones on all components of Virchow's triad (53), that is, venous endothelium, smooth muscle, coagulability of the blood including platelets (irritability as well as content), and components of the coagulation cascade (M. P. Bracamonte, M. Jayachandran, K. S. Rud, and V. M. Miller, unpublished observation, and Refs. 27, 34).
In summary, sex and hormonal status influence responses of veins to platelets and platelet-derived products. These differences represent effects of ovarian hormones on the smooth muscle, as contractions to KCl, 5-HT, and prostacyclin differ between veins from intact and ovariectomized female animals. Differences in responses are also affected by sex and/or testosterone, as contractions to platelets and endothelium-derived contractile factors differ between veins from male and female ovariectomized animals.
FOOTNOTES
Address for reprint requests and other correspondence: V. M. Miller, Depts. of Surgery, Physiology and Biophysics, Mayo Clinic and Foundation, Medical Sciences Bldg. 4-62A, 200 First St. SW, Rochester, MN 55905 (E-mail: miller.virginia@mayo.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 21 June 2001; accepted in final form 17 September 2001.
REFERENCES
1.Balfour, JA, and Goa KL. Raloxifene. Drugs Aging 12: 335-341, 1998.
2.Banks, M, Wei C-M, Kim CH, Burnett JC, Jr, and Miller VM. Mechanism of relaxations to C-type natriuretic peptide in veins. Am J Physiol Heart Circ Physiol 271: H1907-H1911, 1996.
3.Barber, DA, Burnett JC, Jr, and Miller VM. Gender differences in relaxations evoked by C-type natriuretic peptide in porcine coronary arteries. Endothelium 2: S2, 1995.
4.Barber, DA, Sieck GC, Fitzpatrick LA, and Miller VM. Endothelin receptors are modulated in association with endogenous fluctuations in estrogen. Am J Physiol Heart Circ Physiol 271: H1999-H2006, 1996.
5.Barber, DA, and Miller VM. Gender differences in endothelium-dependent relaxations do not involve NO in porcine coronary arteries. Am J Physiol Heart Circ Physiol 273: H2325-H2332, 1997.
6. Barber D and Miller V. Endothelium-dependent vasoconstrictors. Endothel Cell Res 167-185, 1998.
7.Barber, DA, Sieck GC, Fitzpatrick LA, and Miller VM. Endothelin receptors are modulated in association with endogenous fluctuations in estrogen. Am J Physiol Heart Circ Physiol 271: H1999-H2006, 1996.
8.Barrett-Connor, E, and Bush TL. Estrogen and coronary heart disease in women. JAMA 265: 1861-1867, 1991.
9.Boyle, MB, MacLusky NJ, Naftolin F, and Kaczmarek LK. Hormonal regulation of K+ channel messenger RNA in rat myometrium during oestrus cycle and in pregnancy. Nature 330: 373-375, 1987.
12.Caulin-Glaser, T, Garcia-Cardena G, Sarrel P, Sessa WC, and Bender JR. 17-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res 81: 885-892, 1997.
13.Chang, A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, Fisher H, Rosenthal J, Witte R, Schinella R, and Trump D. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 14: 2250-2257, 1996.
14.Cohen, RA, Shepherd JT, and Vanhoutte PM. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science 221: 273-274, 1983.
15.Colucci, WS, Gimbrone MA, Jr, McLaughlin MK, Halpern W, and Alexander RW. Increased vascular catecholamine sensitivity and -adrenergic receptor affinity in female and estrogen-treated male rats. Circ Res 50: 805-811, 1982.
16.Cushman, M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, and Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 19: 893-899, 1999.
17.Cuzick, J. A brief review of the current breast cancer prevention trials and proposals for future trials. Eur J Cancer 36: 1298-1302, 2000.
18.Freay, AD, Curtis SW, Korach KS, and Rubanyi GM. Mechanism of vascular smooth muscle relaxation by estrogen in depolarized rat and mouse aorta. Role of nuclear estrogen receptor and Ca2+ uptake. Circ Res 81: 242-248, 1997.
19.Gallagher, PE, Li P, Lenhart JR, Chappell MC, and Brosnihan KB. Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension 33: 323-328, 1999.
20.Geary, GG, Krause DN, and Duckles SP. Estrogen reduces mouse cerebral artery tone through endothelial NOS- and cyclooxygenase-dependent mechanisms. Am J Physiol Heart Circ Physiol 279: H511-H519, 2000.
21.Grady, D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, and Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The heart and estrogen/progestin replacement study. Ann Intern Med 132: 689-696, 2000.
22.Harder, DR, and Coulson PB. Estrogen receptors and effects of estrogen on membrane electrical properties of coronary vascular smooth muscle. J Cell Physiol 100: 375-382, 1979.
23.Hennekens, CH, Dyken ML, and Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 96: 2751-2753, 1997 .
24.Hoibraaten, E, Abdelnoor M, and Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism. A population-based case-control study. Thromb Haemost 82: 1218-1221, 1999.
25.Houston, DS, Shepherd JT, and Vanhoutte PM. Aggregating human platelets cause direct contraction and endothelium-dependent relaxation of isolated canine coronary arteries. J Clin Invest 78: 539-544, 1986.
26.Houston, DS, Shepherd JT, and Vanhoutte PM. Adenine nucleotides, serotonin, and endothelium-dependent relaxations to platelets. Am J Physiol Heart Circ Physiol 248: H389-H395, 1985.
27.Jayachandran, M, Hayashi T, Sumi D, Iguchi A, and Miller VM. Temporal effects of 17-estradiol on caveolin-1 mRNA and protein in bovine aortic endothelial cells. Am J Physiol Heart Circ Physiol 281: H1327-H1333, 2001.
29.Jick, H, Derby LE, Myers MW, Vasilakis C, and Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348: 981-983, 1996.
30.Kannel, WB, Hjortland MC, McNamara PM, and Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 85: 447-452, 1976.
31.Komori, K, Gloviczki P, Bourchier RG, Miller VM, and Vanhoutte PM. Endothelium-dependent vasorelaxations in response to aggregating platelets are impaired in reversed vein grafts. J Vasc Surg 12: 139-147, 1990.
32.Komori, K, Shimokawa H, and Vanhoutte PM. Endothelium-dependent relaxation in response to aggregating platelets in porcine femoral veins and its modulation by diet. Circulation 80: 401-409, 1989.
33.Lewis, DA, and Miller VM. Role of lipoxygenase and cytochrome-P450 in the production of endothelium-derived relaxing factors in canine femoral veins. J Cardiovasc Pharmacol 20: 401-407, 1992.
34.Luyer, MDP, Khosla S, Owen WG, and Miller VM. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 86: 3629-3634, 2001.
35.McGoon, MD, and Vanhoutte PM. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest 74: 828-833, 1984.
36.Miller, VM. Selective production of endothelium-derived nitric oxide in canine femoral veins. Am J Physiol Heart Circ Physiol 261: H677-H682, 1991.
37.Miller, VM, Lewis DA, and Barber DA. Gender differences and endothelium- and platelet-derived factors in the coronary circulation. Clin Exp Pharmacol Physiol 26: 132-136, 1999.
38.Miller, VM, and Vanhoutte PM. Is nitric oxide the only endothelium-derived relaxing factor in canine femoral veins? Am J Physiol Heart Circ Physiol 257: H1910-H1916, 1989.
39.Miller, VM, and Vanhoutte PM. Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclooxygenase. Am J Physiol Heart Circ Physiol 248: H432-H437, 1985.
40.Moncada, S, Gryglewski R, Bunting S, and Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663-665, 1976.
41.Nickenig, G, Baumer AT, Grohe C, Kahlert S, Strehlow K, Rosenkranz S, Stablein A, Beckers F, Smits JFM, Daemen MJAP, Vetter H, and Bohm M. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 97: 2197-2201, 1998.
42.Polderman, KH, Stehouwer CDA, van Kamp GJ, Dekker GA, Verheugt FWA, and Gooren LJG Influence of sex hormones on plasma endothelin levels. Ann Intern Med 118: 429-432, 1993.
43.Prakash, YS, Togaibayeva AA, Kannan MS, Miller VM, Fitzpatrick LA, and Sieck GC. Estrogen increases [Ca2+] efflux from female porcine coronary arterial smooth muscle. Am J Physiol Heart Circ Physiol 276: H926-H934, 1999.
44.Radomski, MW, Palmer RM, and Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 148: 1482-1489, 1987.
45.Raines, EW, and Ross R. Platelet-derived growth factor. J Biol Chem 257: 5154-5160, 1982.
46.Rubio-Gayosso, I, Sierra-Ramirez A, Garcia-Vazquez A, Martinez-Martinez A, Munoz-Garcia O, Morato T, and Ceballos RG. 17-Estradiol increases intracellular calcium concentration through a short-term and nongenomic mechanism in rat vascular endothelium in culture. J Cardiovasc Pharmacol 36: 196-202, 2000.
47.Shaul, PW. Rapid activation of endothelial nitric oxide synthase by estrogen. Steroids 64: 28-34, 1999.
48.Sly, MK, Prager MD, Eberhart RC, Jessen ME, and Kulkarni PV. Inhibition of surface-induced platelet activation by nitric oxide. ASAIO J 41: 394-398, 1995.
49.Stampfer, MJ, Colditz GA, and Willett WC. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 325: 756-762, 1991.
50.Van Kesteren, PJM, Asscheman H, Megens JAJ, and Gooren LJG Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 47: 337-342, 1997.
51.Varas-Lorenzo, C, Garcia-Rodriguez LA, Perez-Gutthann S, and Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction A population-based nested case-control study. Circulation 101: 2572-2578, 2000.
52.Vidal, M, Vanhoutte PM, and Miller VM. Dissociation between endothelium-dependent relaxations and increases in cyclic GMP in systemic veins. Am J Physiol Heart Circ Physiol 260: H1531-H1537, 1991.
53.Virchow, RLK Phlogose und thrombose in gefassystem. In: Gesammelte Abhandlungen zur wisenshcaftlichen Medizin. Frankfurt, Germany: Von Meidinger Sohn, 1856.
54.Wang, X, Barber DA, Lewis DA, McGregor CGA, Sieck GA, Fitzpatrick LA, and Miller VM. Gender and transcriptional regulation of NO synthase and ET-1 in porcine aortic endothelial cells. Am J Physiol Heart Circ Physiol 273: H1962-H1967, 1997.
55.Wennberg, PW, Miller VM, Rabelink T, and Burnett JC, Jr. Further attenuation of endothelium-dependent relaxation imparted by natriuretic peptide receptor antagonism. Am J Physiol Heart Circ Physiol 277: H1618-H1621, 1999.
56.White, RE, Darkow DJ, and Falvo Lang JL. Estrogen relaxes coronary arteries by opening BK Ca channels through a cGMP-dependent mechanism. Circ Res 77: 936-942, 1995.(D. A. Lewis, M. P. Bracam)
Departments of Surgery, and Physiology and Biophysics, Mayo Clinic and Foundation, Rochester, Minnesota 55905
ABSTRACT
Estrogen replacement increases risk of venous thrombosis. In this study, we determined responses in vitro to platelets and platelet products in veins from adult male and intact and ovariectomized female pigs. When contracted with prostaglandin F2, platelets (25,000 platelets/μl) caused relaxation in veins with endothelium. Higher numbers of platelets caused contraction in veins with and without endothelium. In veins without endothelium, contractions were greater in veins from male than in veins from female pigs, and contractions in intact female pig veins were greater than in ovariectomized females pig veins. Platelet products 5-hydroxytryptamine and thromboxane (analog U-46619) caused comparable contractions in all veins; contractions to prostacyclin were less in veins from intact female pigs. ADP caused comparable endothelium-dependent relaxations in all groups. These relaxations were increased by indomethacin in veins from intact males and females; with inhibition of nitric oxide, relaxations were comparable in all groups. These results suggest that venous responses to platelets vary with sex and presence of ovaries in female pigs. These variations reflect differences in type and quantity of substances released from platelets as well as the sensitivity of the smooth muscle to some vasoactive substances. In addition, products of cyclooxygenase may reduce endothelium-dependent relaxations in veins.
keywords:estrogen; venous thrombosis
INTRODUCTION
OBSERVATIONAL AND EPIDEMIOLOGICAL studies indicate that the incidence of arterial cardiovascular disease is less in premenopausal women compared with age-matched men. The incidence of cardiovascular disease increases with menopause, and estrogen-replacement therapy provides primary protection against the development of cardiovascular disease (8, 30, 49, 51). However, although estrogen replacement provides primary protection against development of arterial vascular disease in women, it increases risk for venous thrombosis (16, 21, 24, 29). Estrogen therapy in men also increases the risk of venous thrombosis (13, 50).
Responses of arteries to various vasoactive substances vary by the sex of the animal from which the tissue is derived. Some of these differences are partly due to actions of estrogen on the arterial wall through several mechanisms, including regulation of ion fluxes and receptors on the smooth muscle and production of endothelium-derived factors (6, 7, 12, 15, 18-20, 22, 41-43, 46, 47, 56). No studies have examined sex differences in responses of veins to substances associated with platelet aggregation or thrombosis. This information is important because synthetic estrogen-like compounds (selective estrogen receptor modulators or SERMS) are being developed for tissue-specific therapies for use in both men and women. Two such compounds now in clinical use, tamoxifen and raloxifene, also increase risk for venous thrombosis in women (1, 17). If SERMS are to be used for cardioprotection, it is important to identify potential gender differences not only in arteries but also in veins so that the risk of venous thrombosis can be reduced in both men and women.
Previous work from our laboratory (37) identified differences in the content of platelets from male and female pigs: platelets from adult male pigs contained more thromboxane, whereas platelets from ovariectomized female pigs contained more prostacyclin and 5-hydroxytryptamine (5-HT). However, acute vasomotor responses of the coronary arteries to platelets were found not to vary by sex of the animals (37). The present study was designed to compare responses to platelets and platelet-derived products in veins from gonadally intact male and female animals and to identify whether depletion of ovarian hormone alters the responses in female animals.
METHODS
Femoral veins from 6-mo-old male (139.5 ± 10.2 kg), female (94.4 ± 2.2 kg), and ovariectomized female (87.4 ± 1.4 kg) Yorkshire pigs were used in these experiments. Ovariectomy was performed when female animals were 5 mo old, and veins were removed 4 wk postoperatively. All animals were fed Lean Grow 93 (Land O'Lakes Farmland Feed, Fort Dodge, IA). Gonadally intact females showed changes in their external genitalia associated with changes in their estrus cycle. Estradiol levels typically range from 5 to 35 pg/ml in intact female pigs, are below the level of assay sensitivity in ovariectomized female pigs, and range from 25 to 55 pg/ml in male pigs (4, 5, 54). Testosterone averages 324 ± 99 pg/ml in male pigs (4, 5, 54). Animals were anesthetized with a combination of ketamine hydrochloride (30 mg/kg), xylazine (6 mg/kg), and butorphanol (0.3 mg/kg) intramuscularly. Blood (500 ml) was obtained from the carotid artery for preparation of platelets (see Platelet Preparation below). Femoral veins were excised bilaterally and placed in cold modified Krebs-Ringer bicarbonate solution (control solution), which contained (in mmol/l) 118.3 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25.0 NaHCO3, 0.026 edentate calcium disodium, and 11.1 glucose. Coronary arteries from these animals were studied in separate experiments (5, 37).
Organ Chamber Experiments
After we removed the adventitia, femoral veins were cut into rings; rings that contained valves were excluded from the study. In some rings, the endothelium was removed by gently rubbing the luminal surface with watchmaker's forceps. Because veins vary in length, branching, and the presence of valves, it was not possible to obtain the same number of rings from all animals. However, pairs of rings with and without endothelium or in the absence and presence of either indomethacin (105 mol/l) or NG-monomethyl-L-arginine (L-NMMA, 104 mol/l) plus indomethacin were studied in parallel from a single animal.
Rings were suspended between a fixed point and a force transducer (Statham UC-2) in organ chambers (25 ml) containing control solution at 37°C and were bubbled with 95% O2-5% CO2.
Passive tension on the rings was progressively increased. Active tension to norepinephrine (3 × 107 mol/l) was measured at each passive tension until each ring reached its optimal point on the length-tension curve. Maximal tension to KCl (60 mmol/l) was obtained in all rings. From a given animal, rings with and without endothelium or in the absence and presence of inhibitors were then studied in one of three experimental protocols (protocol A, B, or C).
Experimental protocol A. Rings were contracted with prostaglandin F2 (2 × 106 mol/l), and, once the contraction plateaued, concentration-response curves to ADP (1 × 108 to 1 × 104 mol/l) were obtained. After a washout and equilibration period, responses to autologous platelets (25,000, 50,000, and 75,000 platelets/μl) were obtained during a second contraction to prostaglandin F2.
Experimental protocol B. Concentration-response curves to 5-HT (1 × 1010 to 1 × 106 mol/l) were obtained from baseline tension. After a washout and equilibration period, rings were contracted with prostaglandin F2 (2 × 106 mol/l) and cumulative responses to thrombin (0.01, 0.1 & 1.0 U/ml) were obtained, followed by the calcium ionophore A-23187 (1 × 109 to 1 × 106 mol/l) in rings with endothelium or by nitric oxide (3 × 109 to 1 × 105 mol/l) in rings without endothelium.
Experimental protocol C. Cumulative concentration-response curves were obtained to either the thromboxane mimetic U-46619 (109 to 106 mol/l) or prostacyclin (109 to 105 mol/l) from baseline tension.
In all protocols, at the conclusion of each concentration-response curve measurement, rings were washed with control solution three times. A minimum 20-min equilibration was allowed in all experiments before the next antagonist was tested. Once an inhibitor was added to a chamber, it remained in contact with the tissue for each subsequent stimulation.
Platelet Preparation
Platelets were isolated as previously described (14, 25). Briefly, blood (500 ml) was drawn from the carotid artery into 50-ml centrifuge tubes containing an initial acid citrate dextrose solution [ACD 1, which contained (in mmol/l) 93 sodium citrate, 70 citric acid, and 140 dextrose] so that the concentration was 10 ml of blood to 1 ml of ACD 1. The blood-ACD 1 solution was centrifuged at 55 g for 40 min. The plasma was removed, and an equal volume of a second acid citrate dextrose solution [ACD 2, which contained (in mmol/l) 185.7 sodium citrate, 14 citric acid, 209.8 dextrose, and 9.9 potassium chloride] was added to each tube of plasma. The plasma-ACD 2 solution was centrifuged at 570 g for 40 min at room temperature. The supernatant was discarded, and the platelet pellet was resuspended in ACD 2 (1.25 ml ACD 2 for each 50 ml of original blood). The platelet number in this suspension was obtained by a Coulter counter. Once the platelet count in the suspension was known, volumes could be adjusted so that the final platelet concentration was standard for each experiment (25,000, 50,000, or 75,000 platelets/μl).
Calculations and Statistical Analysis
Data are expressed as means ± SE; n equals the number of pigs from which rings were taken. Data for contractions are expressed as the increase in grams of tension or as a percentage of the contraction to KCl. For relaxations, data are expressed as percent change in tension to prostaglandin F2 from a submaximal contraction. In some veins, spontaneous activity was observed. Peak tension was used as the value for which further changes in tension were measured. One-way ANOVA was performed on the calculated areas under individual concentration-response curves, maximal tensions, or, when appropriate, the concentration at 50% maximal relaxation or contraction (EC50), expressed as a negative log molar concentration. If a significant F value was found, a Bonferroni test was used to determine differences among means. Alpha level was set at 0.05.
RESULTS
The number of platelets in the prepared suspension did not differ significantly among groups: 93 ± 6 × 103 platelets/μl in male pigs (n = 14), 106 ± 10 × 103 platelets/μl in female pigs (n = 16), and 100 ± 7 × 103 platelets/μl in ovariectomized female pigs (n = 10). All rings contracted to KCl (Table 1). Contractions to KCl were similar between rings with and without endothelium within each group. However, contractions of veins with endothelium from intact female pigs were significantly less than those from veins with endothelium from male pigs (Table 1).
Responses to Platelets
Platelets at a concentration of 25,000 platelets/μl caused endothelium-dependent relaxations in veins from all groups of pigs, whereas higher concentrations of platelets caused contractions in rings with and without endothelium. In rings without endothelium, contractions were as follows: male > female > ovariectomized female pigs (Figs. 1 and 2).
Contractions to Platelet-Derived Factors
5-HT caused comparable concentration-dependent contractions of rings with and without endothelium from all groups of pigs. Absolute tension developed to 106 M 5-HT was less in veins with endothelium from females compared with male and ovariectomized pigs: 6.3 ± 0.9 g (n = 11) in males, 2.4 ± 0.4 g (n = 15) in intact females, and 6.5 ± 1.7 g (n = 9) in ovariectomized females. Tensions were not altered significantly by removal of the endothelium. When expressed as a percentage of the maximal tension to KCl, the sensitivity of veins without endothelium from ovariectomized pigs was less than that of veins from either intact male or female pigs (Fig. 3).
Both U-46619 and prostacyclin caused concentration-dependent contractions in veins with and without endothelium from all groups of pigs (Fig. 4). There was large variability in responses, especially in rings without endothelium. However, maximal contractions to prostacyclin in female pig veins without endothelium were significantly less than the contractions in ovariectomized female pig veins. Prostacyclin did not cause a significant change in tension if the veins were first contracted with prostaglandin F2 (data not shown, n = 5/group).
Relaxations to Platelet-Derived Factors
In veins with endothelium contracted with prostaglandin F2, ADP caused comparable concentration-dependent relaxations in veins from all groups of pigs (Fig. 5). However, incubation of the rings with indomethacin caused a significant increase in sensitivity and maximal relaxation in veins with endothelium from male pigs. Maximal relaxations were also increased significantly in veins from intact females. Inhibition of production of nitric oxide with L-NMMA significantly reduced maximal relaxation and decreased sensitivity in veins from male pigs but not from either intact or ovariectomized females (Fig. 6). Relaxations of rings without endothelium were not different among groups, with a maximal relaxation averaging a decrease of ~25% of the contraction to prostaglandin F2. Relaxations of rings without endothelium were not altered significantly by indomethacin alone or by the combination of indomethacin plus L-NMMA (data not shown).
Thrombin also caused concentration-dependent relaxations in veins from all groups of pigs. However, unlike responses to ADP, relaxations to thrombin were not significantly inhibited by incubation of veins with either indomethacin alone or with a combination of indomethacin plus L-NMMA (Fig. 6).
Both A-23187 and nitric oxide caused comparable relaxations of rings with and without endothelium, respectively, in veins from all groups (Fig. 7). These relaxations were unaffected by incubation of the veins with either indomethacin or a combination of indomethacin plus L-NMMA (data not shown).
DISCUSSION
Results of this study suggest that the response to platelets in veins vary depending on the sex of the animal from which they are derived and, for female animals, on the presence of ovaries. These differences were most obvious in expression of contractions to the platelets in the absence of endothelium: contractions of veins from ovariectomized female pigs were less than those from intact male and female pigs. These observations in part confirm previous studies that indicated that factors released from aggregating platelets cause endothelium-dependent relaxations in the presence of endothelium and contractions in the absence of endothelium (14, 25, 26, 32, 35). Thus an aggregation of platelets may not be retained after dilation of a blood vessel with intact endothelium. However, with either mechanical or chemical damage to the endothelium, platelet aggregation, once initiated, would cause constriction of the venous wall. The constriction-decreased cross-sectional area results in increased flow velocities through the site, which would tend to wash off excess platelets and prevent an occlusive thrombus (14). Irritability of platelets, i.e., the tendency to form an aggregate, is also increased with ovariectomy (unpublished observations from our laboratory). Ovarian hormones modulate the content of vasoactive substances in platelets (shown here and in Ref. 37) as well as other factors of the coagulation cascade involved in thrombus formation (34). Therefore, under conditions of hormone depletion and/or replacement, additional factors may affect expansion and retention of the platelet aggregate, although a normal part of hemostasis may contribute to thrombosis in pathological situations.
Contractions to platelets in veins without endothelium from ovariectomized females were significantly less than contractions of veins from intact males. This result was unexpected. Contractions to KCl were similar between veins from males and ovariectomized females, thus demonstrating similar contractile characteristics of the smooth muscle. Therefore, reduced contractions to platelet products in veins from ovariectomized compared with male pigs most likely represent differences in the various factors released from the aggregating platelets. For example, release of 5-HT and prostacyclin is greater from platelets of ovariectomized pigs compared with either intact male or female pigs (37). Platelet-derived 5-HT causes platelet-associated contractions of other blood vessels (14, 25, 26, 32, 35); indeed, 5-HT directly caused contraction of the femoral veins from these animals, albeit with a decreased sensitivity compared with veins from intact male or female animals. In addition, prostacyclin caused contraction of the veins from ovariectomized females. Therefore, prostacyclin, if released from platelets, would contribute to contraction rather than relaxation. ADP is also released from platelets (25, 26, 31) and, although not quantified in this study, causes relaxation of veins with and without endothelium (25, 26, 31). In addition, platelets contain other vasoactive and mitogenic factors, including nitric oxide, cyclic guanosine monophosphate, and platelet-derived growth factor, some of which are modulated by ovarian hormones (M. Jayachandran and V. M. Miller, unpublished observations, and Ref. 45). Nitric oxide released from platelets of ovariectomized pigs would functionally antagonize contractions to 5-HT and prostacyclin. Other studies need to quantify nitric oxide from platelets of animals of differing gonadal and hormonal status. Unpublished observations from our laboratory indicate that megakaryocytes, the precursors of platelets, contain estrogen receptors. Therefore, gonadal hormones may alter content of platelets through genomic mechanisms in these cells. Despite the lack of such quantification of all factors in platelets in the present study, it is likely that the response to aggregating platelets in veins, as in arteries, represents the cumulative effect of all platelet-derived products released during aggregation.
The diet of the pigs contained soy as one protein source. Phytoestrogens can bind to estrogen receptors and act as antioxidants. It is not known at this time how these compounds regulate estrogen receptor expression or compete with binding to receptors when endogenous estrogen is present. At least in the ovariectomized pigs that lacked endogenous ovarian hormones including estrogen, the dietary source of phytoestrogens may have modulated platelet responses such that even greater differences may have been observed between responses to platelets in veins from intact and ovariectomized pigs if the diet did not contain soy.
Responses to platelets do not only reflect differences in the content of vasoactive factors in platelets but also differences in functions of the smooth muscle and endothelium. Contractions to KCl were decreased in veins from intact female pigs compared with other groups. Ovarian hormones modulate expression of potassium channels in uterine smooth muscle (9), but similar regulation needs to be demonstrated in venous smooth muscle. Inhibition of potassium channels decreases endothelium-dependent relaxations in veins from intact female animals to a greater extent than in veins from ovariectomized female animals (M. P. Bracamonte, M. Jayachandran, K. S. Rud, and V. M. Miller, unpublished observations, and Bracamonte, Rud, and Miller, unpublished observations). Therefore, ovarian status may influence mechanisms associated with regulation of potassium and membrane polarization in veins. Sex differences in activation of potassium channels were also observed in coronary arterial smooth muscle (3, 22). It is unclear why contractions to prostacyclin are less in veins from intact female pigs compared with the other groups. Differences in activation of cAMP cannot be excluded at this time. Because relaxations to nitric oxide were similar among groups, it is unlikely that activation of soluble guanylate cyclase is altered by sex or gonadal status.
Endothelium-dependent relaxations to ADP, thrombin, or A-23187 were similar among groups. However, indomethacin had different effects on these responses in veins from male compared with female pigs, especially as related to increased relaxation to ADP in males and the tendency for decreased relaxations to thrombin in females. As in coronary arteries, endothelium-dependent relaxations in veins from male animals increased with inhibition of cyclooxygenase (5), suggesting a greater contribution of contractile products of arachidonic acid metabolism in male than in female animals. Exogenous arachidonic acid causes endothelium-dependent contractions of femoral veins from gonadally intact male dogs (39). Thromboxane synthase may be modulated by testosterone, since amounts of thromboxane measured from activated platelets were greater in male than in female animals (37). Increased amounts of thromboxane in platelets and evidence of a cyclooxygenase contractile factor from the endothelium of males suggest that products of arachidonic acid metabolism may be modulated similarly in several cell types by sex steroids. If similar conditions could be demonstrated in humans, results could account in part for the effectiveness of aspirin to limit cardiovascular disease in men (23).
Observations that inhibition of neither cyclooxygenase nor L-NMMA blocks endothelium-dependent relaxations to thrombin or A-23187 in veins are not new (36, 38, 52) and suggest release of other endothelium-derived factors; these remain to be characterized. Possible candidates for other endothelium-derived factors include products of lipoxygenase and/or C-type natriuretic factor (2, 33, 55). These factors would not only affect venous tone but also would act to release factors from the endothelium that would in turn affect platelet aggregation (40, 44, 48). Therefore, changes in risk for venous thrombosis with initiation of estrogen-replacement therapies would represent the combined effects of the hormones on all components of Virchow's triad (53), that is, venous endothelium, smooth muscle, coagulability of the blood including platelets (irritability as well as content), and components of the coagulation cascade (M. P. Bracamonte, M. Jayachandran, K. S. Rud, and V. M. Miller, unpublished observation, and Refs. 27, 34).
In summary, sex and hormonal status influence responses of veins to platelets and platelet-derived products. These differences represent effects of ovarian hormones on the smooth muscle, as contractions to KCl, 5-HT, and prostacyclin differ between veins from intact and ovariectomized female animals. Differences in responses are also affected by sex and/or testosterone, as contractions to platelets and endothelium-derived contractile factors differ between veins from male and female ovariectomized animals.
FOOTNOTES
Address for reprint requests and other correspondence: V. M. Miller, Depts. of Surgery, Physiology and Biophysics, Mayo Clinic and Foundation, Medical Sciences Bldg. 4-62A, 200 First St. SW, Rochester, MN 55905 (E-mail: miller.virginia@mayo.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 21 June 2001; accepted in final form 17 September 2001.
REFERENCES
1.Balfour, JA, and Goa KL. Raloxifene. Drugs Aging 12: 335-341, 1998.
2.Banks, M, Wei C-M, Kim CH, Burnett JC, Jr, and Miller VM. Mechanism of relaxations to C-type natriuretic peptide in veins. Am J Physiol Heart Circ Physiol 271: H1907-H1911, 1996.
3.Barber, DA, Burnett JC, Jr, and Miller VM. Gender differences in relaxations evoked by C-type natriuretic peptide in porcine coronary arteries. Endothelium 2: S2, 1995.
4.Barber, DA, Sieck GC, Fitzpatrick LA, and Miller VM. Endothelin receptors are modulated in association with endogenous fluctuations in estrogen. Am J Physiol Heart Circ Physiol 271: H1999-H2006, 1996.
5.Barber, DA, and Miller VM. Gender differences in endothelium-dependent relaxations do not involve NO in porcine coronary arteries. Am J Physiol Heart Circ Physiol 273: H2325-H2332, 1997.
6. Barber D and Miller V. Endothelium-dependent vasoconstrictors. Endothel Cell Res 167-185, 1998.
7.Barber, DA, Sieck GC, Fitzpatrick LA, and Miller VM. Endothelin receptors are modulated in association with endogenous fluctuations in estrogen. Am J Physiol Heart Circ Physiol 271: H1999-H2006, 1996.
8.Barrett-Connor, E, and Bush TL. Estrogen and coronary heart disease in women. JAMA 265: 1861-1867, 1991.
9.Boyle, MB, MacLusky NJ, Naftolin F, and Kaczmarek LK. Hormonal regulation of K+ channel messenger RNA in rat myometrium during oestrus cycle and in pregnancy. Nature 330: 373-375, 1987.
12.Caulin-Glaser, T, Garcia-Cardena G, Sarrel P, Sessa WC, and Bender JR. 17-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res 81: 885-892, 1997.
13.Chang, A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, Fisher H, Rosenthal J, Witte R, Schinella R, and Trump D. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 14: 2250-2257, 1996.
14.Cohen, RA, Shepherd JT, and Vanhoutte PM. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science 221: 273-274, 1983.
15.Colucci, WS, Gimbrone MA, Jr, McLaughlin MK, Halpern W, and Alexander RW. Increased vascular catecholamine sensitivity and -adrenergic receptor affinity in female and estrogen-treated male rats. Circ Res 50: 805-811, 1982.
16.Cushman, M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, and Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 19: 893-899, 1999.
17.Cuzick, J. A brief review of the current breast cancer prevention trials and proposals for future trials. Eur J Cancer 36: 1298-1302, 2000.
18.Freay, AD, Curtis SW, Korach KS, and Rubanyi GM. Mechanism of vascular smooth muscle relaxation by estrogen in depolarized rat and mouse aorta. Role of nuclear estrogen receptor and Ca2+ uptake. Circ Res 81: 242-248, 1997.
19.Gallagher, PE, Li P, Lenhart JR, Chappell MC, and Brosnihan KB. Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension 33: 323-328, 1999.
20.Geary, GG, Krause DN, and Duckles SP. Estrogen reduces mouse cerebral artery tone through endothelial NOS- and cyclooxygenase-dependent mechanisms. Am J Physiol Heart Circ Physiol 279: H511-H519, 2000.
21.Grady, D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, and Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The heart and estrogen/progestin replacement study. Ann Intern Med 132: 689-696, 2000.
22.Harder, DR, and Coulson PB. Estrogen receptors and effects of estrogen on membrane electrical properties of coronary vascular smooth muscle. J Cell Physiol 100: 375-382, 1979.
23.Hennekens, CH, Dyken ML, and Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 96: 2751-2753, 1997 .
24.Hoibraaten, E, Abdelnoor M, and Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism. A population-based case-control study. Thromb Haemost 82: 1218-1221, 1999.
25.Houston, DS, Shepherd JT, and Vanhoutte PM. Aggregating human platelets cause direct contraction and endothelium-dependent relaxation of isolated canine coronary arteries. J Clin Invest 78: 539-544, 1986.
26.Houston, DS, Shepherd JT, and Vanhoutte PM. Adenine nucleotides, serotonin, and endothelium-dependent relaxations to platelets. Am J Physiol Heart Circ Physiol 248: H389-H395, 1985.
27.Jayachandran, M, Hayashi T, Sumi D, Iguchi A, and Miller VM. Temporal effects of 17-estradiol on caveolin-1 mRNA and protein in bovine aortic endothelial cells. Am J Physiol Heart Circ Physiol 281: H1327-H1333, 2001.
29.Jick, H, Derby LE, Myers MW, Vasilakis C, and Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348: 981-983, 1996.
30.Kannel, WB, Hjortland MC, McNamara PM, and Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 85: 447-452, 1976.
31.Komori, K, Gloviczki P, Bourchier RG, Miller VM, and Vanhoutte PM. Endothelium-dependent vasorelaxations in response to aggregating platelets are impaired in reversed vein grafts. J Vasc Surg 12: 139-147, 1990.
32.Komori, K, Shimokawa H, and Vanhoutte PM. Endothelium-dependent relaxation in response to aggregating platelets in porcine femoral veins and its modulation by diet. Circulation 80: 401-409, 1989.
33.Lewis, DA, and Miller VM. Role of lipoxygenase and cytochrome-P450 in the production of endothelium-derived relaxing factors in canine femoral veins. J Cardiovasc Pharmacol 20: 401-407, 1992.
34.Luyer, MDP, Khosla S, Owen WG, and Miller VM. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 86: 3629-3634, 2001.
35.McGoon, MD, and Vanhoutte PM. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest 74: 828-833, 1984.
36.Miller, VM. Selective production of endothelium-derived nitric oxide in canine femoral veins. Am J Physiol Heart Circ Physiol 261: H677-H682, 1991.
37.Miller, VM, Lewis DA, and Barber DA. Gender differences and endothelium- and platelet-derived factors in the coronary circulation. Clin Exp Pharmacol Physiol 26: 132-136, 1999.
38.Miller, VM, and Vanhoutte PM. Is nitric oxide the only endothelium-derived relaxing factor in canine femoral veins? Am J Physiol Heart Circ Physiol 257: H1910-H1916, 1989.
39.Miller, VM, and Vanhoutte PM. Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclooxygenase. Am J Physiol Heart Circ Physiol 248: H432-H437, 1985.
40.Moncada, S, Gryglewski R, Bunting S, and Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663-665, 1976.
41.Nickenig, G, Baumer AT, Grohe C, Kahlert S, Strehlow K, Rosenkranz S, Stablein A, Beckers F, Smits JFM, Daemen MJAP, Vetter H, and Bohm M. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 97: 2197-2201, 1998.
42.Polderman, KH, Stehouwer CDA, van Kamp GJ, Dekker GA, Verheugt FWA, and Gooren LJG Influence of sex hormones on plasma endothelin levels. Ann Intern Med 118: 429-432, 1993.
43.Prakash, YS, Togaibayeva AA, Kannan MS, Miller VM, Fitzpatrick LA, and Sieck GC. Estrogen increases [Ca2+] efflux from female porcine coronary arterial smooth muscle. Am J Physiol Heart Circ Physiol 276: H926-H934, 1999.
44.Radomski, MW, Palmer RM, and Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 148: 1482-1489, 1987.
45.Raines, EW, and Ross R. Platelet-derived growth factor. J Biol Chem 257: 5154-5160, 1982.
46.Rubio-Gayosso, I, Sierra-Ramirez A, Garcia-Vazquez A, Martinez-Martinez A, Munoz-Garcia O, Morato T, and Ceballos RG. 17-Estradiol increases intracellular calcium concentration through a short-term and nongenomic mechanism in rat vascular endothelium in culture. J Cardiovasc Pharmacol 36: 196-202, 2000.
47.Shaul, PW. Rapid activation of endothelial nitric oxide synthase by estrogen. Steroids 64: 28-34, 1999.
48.Sly, MK, Prager MD, Eberhart RC, Jessen ME, and Kulkarni PV. Inhibition of surface-induced platelet activation by nitric oxide. ASAIO J 41: 394-398, 1995.
49.Stampfer, MJ, Colditz GA, and Willett WC. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 325: 756-762, 1991.
50.Van Kesteren, PJM, Asscheman H, Megens JAJ, and Gooren LJG Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 47: 337-342, 1997.
51.Varas-Lorenzo, C, Garcia-Rodriguez LA, Perez-Gutthann S, and Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction A population-based nested case-control study. Circulation 101: 2572-2578, 2000.
52.Vidal, M, Vanhoutte PM, and Miller VM. Dissociation between endothelium-dependent relaxations and increases in cyclic GMP in systemic veins. Am J Physiol Heart Circ Physiol 260: H1531-H1537, 1991.
53.Virchow, RLK Phlogose und thrombose in gefassystem. In: Gesammelte Abhandlungen zur wisenshcaftlichen Medizin. Frankfurt, Germany: Von Meidinger Sohn, 1856.
54.Wang, X, Barber DA, Lewis DA, McGregor CGA, Sieck GA, Fitzpatrick LA, and Miller VM. Gender and transcriptional regulation of NO synthase and ET-1 in porcine aortic endothelial cells. Am J Physiol Heart Circ Physiol 273: H1962-H1967, 1997.
55.Wennberg, PW, Miller VM, Rabelink T, and Burnett JC, Jr. Further attenuation of endothelium-dependent relaxation imparted by natriuretic peptide receptor antagonism. Am J Physiol Heart Circ Physiol 277: H1618-H1621, 1999.
56.White, RE, Darkow DJ, and Falvo Lang JL. Estrogen relaxes coronary arteries by opening BK Ca channels through a cGMP-dependent mechanism. Circ Res 77: 936-942, 1995.(D. A. Lewis, M. P. Bracam)